Department of Psychiatry, University of Connecticut School of Medicine, Farmington, CT 06030-2103, USA.
Psychosomatics. 2010 Mar-Apr;51(2):137-48. doi: 10.1176/appi.psy.51.2.137.
Interferon-alpha (IFN-alpha) treatment frequently induces depression, potentially leading to early dose reductions or a shorter duration of treatment, which can adversely affect outcomes, including quality of life.
Defining relevant risk factors for IFN-alpha-induced depression is essential in order to identify prophylactic treatment strategies.
The authors examined whether a functional polymorphism (5-HTTLPR) in the gene encoding the serotonin transporter moderates IFN-alpha-induced depressive symptoms in 1,015 patients with chronic hepatitis C (CHC) receiving pegylated IFN-alpha and ribavirin. Depressive symptoms were assessed at baseline, 12 weeks, and 20 weeks of treatment.
Depression symptoms increased during antiviral treatment; 5-HTTLPR genotype moderated IFN-alpha-induced depression symptoms in both non-Hispanic Caucasians and Hispanic patients, although the opposite risk allele was associated with depression in the two populations.
5-HTTLPR may moderate risk for the development of depressive symptoms during IFN-alpha therapy for CHC in a population-specific manner.
干扰素-α（IFN-α）治疗常可引发抑郁，这可能导致剂量早期减少或治疗时间缩短，从而对结局（包括生活质量）产生不利影响。
明确与 IFN-α 诱导的抑郁相关的风险因素，对于确定预防治疗策略非常重要。
作者检测了慢性丙型肝炎（CHC）患者接受聚乙二醇干扰素-α和利巴韦林治疗时，编码 5-羟色胺转运体的基因中的功能性多态性（5-HTTLPR）是否可调节 IFN-α 诱导的抑郁症状。在治疗开始时、12 周和 20 周评估抑郁症状。
抗病毒治疗期间抑郁症状增加；5-HTTLPR 基因型在非西班牙裔白人和西班牙裔患者中均调节 IFN-α 诱导的抑郁症状，但两种人群中，相反的风险等位基因与抑郁相关。
5-HTTLPR 可能以特定人群的方式调节 CHC 患者 IFN-α 治疗期间发生抑郁症状的风险。
